StockNews.com Downgrades IQVIA (NYSE:IQV) to Hold

StockNews.com downgraded shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.

IQV has been the subject of a number of other reports. JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Stifel Nicolaus decreased their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Citigroup decreased their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Leerink Partners restated an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Trading Up 1.1 %

IQV opened at $185.47 on Wednesday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $32.70 billion, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The firm has a 50 day simple moving average of $197.14 and a 200 day simple moving average of $211.59. IQVIA has a fifty-two week low of $179.28 and a fifty-two week high of $261.72.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts anticipate that IQVIA will post 10.84 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Synergy Asset Management LLC acquired a new position in IQVIA during the fourth quarter worth $33,000. Avior Wealth Management LLC boosted its holdings in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new position in IQVIA during the fourth quarter worth $39,000. Lee Danner & Bass Inc. bought a new stake in IQVIA during the fourth quarter worth $44,000. Finally, Zions Bancorporation N.A. raised its position in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after acquiring an additional 85 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.